Q1 Was Slow For Deals, But That Could Change With One Big Transaction – PwC
Executive Summary
Life science deal-making declined by volume during the first quarter, but aggregate value was up. Looking ahead, PwC sees an ideal environment for major deals – if something like Takeda/Shire sparks a trend.
You may also be interested in...
BIO Notebook Day 2: Levin Scolds Industry For Squandering Proceeds From US Tax Reform
Former Teva and current Ovid CEO Jeremy Levin says pharma should use tax reform gains for business development, not share buybacks. Also, Patient-focused drug development (PFDD) is about more than just getting new drugs approved, an advocate says, while FDA previews coming guidance on PFDD. And, Alnylam’s CEO reflects on what it took financially to get RNAi to the threshold of its first product approval.
BIO Notebook Day 2: Levin Scolds Industry For Squandering Proceeds From US Tax Reform
Former Teva and current Ovid CEO Jeremy Levin says pharma should use tax reform gains for business development, not share buybacks. Also, Patient-focused drug development (PFDD) is about more than just getting new drugs approved, an advocate says, while FDA previews coming guidance on PFDD. And, Alnylam’s CEO reflects on what it took financially to get RNAi to the threshold of its first product approval.
Deal Watch: Gilead’s Immunology Collaboration With Verily Continues Pivot Away From Virology
Gilead’s tie-up with Google’s Verily will explore the immunological underpinnings of rheumatoid arthritis, lupus and GI disorders. Janssen acquires BeneVir and its oncolytic virus expertise, while United Therapeutics buys out SteadyMed.